This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

Home

Recommendations

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

About RSV

About RSV

Infants at Risk

Individuals ≥ 60 Years of Age

About ABRYSVO

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

Efficacy and Safety Profiles

Clinical Trials

MATISSE Study Design

MATISSE Data

MATISSE Safety Profile

RENOIR Study Design

RENOIR Data

RENOIR Safety Profile

More

Coverage Information

Patient Profiles

FAQ

Resources

Product MonographSafety Information
Pfizer Respiratory Vaccine Portfolio
In infants from birth through 6 months of ageDemonstrated statistically significant reduction in the relative risk of severe MA RSV-LRTD at all timepoints through 180 days vs. placebo1*

Adapted from the ABRYSVO Product Monograph.1

Demonstrated vaccine efficacy data on MA RSV‑LRTD at all timepoints through 180 days1
  • The vaccine efficacy results did not meet the statistical criterion for success (a CI lower bound > 20%) for MA RSV-LRTD.
  • Clinically meaningful differences were observed from 90 days through 180 days after birth.

Adapted from the ABRYSVO Product Monograph.1

Demonstrated vaccine efficacy data against hospitalization due to RSV at all timepoints through 360 days (secondary endpoint)1

Adapted from the ABRYSVO Product Monograph.1

MA: medically attended; RSV: respiratory syncytial virus; LRTD: lower respiratory tract disease; CI: confidence interval
*The statistical criterion for success was defined as a CI lower bound > 20%.
†Evaluable efficacy population.

‡The prespecified success criterion was not met for MA RSV-LRTI at 90 days.

Reference:ABRYSVO Product Monograph. Pfizer Canada ULC. May 29, 2024.
PP-A1G-CAN-0117-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN
Are you a resident of Quebec?